AR090315A1 - Uso de antitrombina en el tratamiento de pre-eclampsia - Google Patents

Uso de antitrombina en el tratamiento de pre-eclampsia

Info

Publication number
AR090315A1
AR090315A1 ARP130100795A ARP130100795A AR090315A1 AR 090315 A1 AR090315 A1 AR 090315A1 AR P130100795 A ARP130100795 A AR P130100795A AR P130100795 A ARP130100795 A AR P130100795A AR 090315 A1 AR090315 A1 AR 090315A1
Authority
AR
Argentina
Prior art keywords
antithrombin
treatment
eclampsy
antitrombin
glycosylation pattern
Prior art date
Application number
ARP130100795A
Other languages
English (en)
Original Assignee
Revo Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revo Biolog Inc filed Critical Revo Biolog Inc
Publication of AR090315A1 publication Critical patent/AR090315A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Métodos para el tratamiento de la preeclampsia y de la preeclampsia severa que comprende administrar antitrombina. Reivindicación 8: El uso de cualquiera de las reivindicaciones 1 - 7, donde la antitrombina tiene un patrón de glicosilación alto en manosa. Reivindicación 9: El uso de cualquiera de las reivindicaciones 1 - 8, donde la antitrombina comprende GaINac (N-acetilgalactosamina). Reivindicación 10: El uso de cualquiera de las reivindicaciones 1 - 9, donde la antitrombina tiene un patrón de glicosilación de fucosa-GlcNAc. Reivindicación 11: El uso de cualquiera de las reivindicaciones 1 - 10, donde la antitrombina es antitrombina transgénicamente producida.
ARP130100795A 2012-03-12 2013-03-12 Uso de antitrombina en el tratamiento de pre-eclampsia AR090315A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261609534P 2012-03-12 2012-03-12

Publications (1)

Publication Number Publication Date
AR090315A1 true AR090315A1 (es) 2014-11-05

Family

ID=49161701

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100795A AR090315A1 (es) 2012-03-12 2013-03-12 Uso de antitrombina en el tratamiento de pre-eclampsia

Country Status (12)

Country Link
US (1) US20140206617A1 (es)
EP (1) EP2825194A4 (es)
JP (1) JP2015509984A (es)
KR (1) KR20140135219A (es)
CN (1) CN104321076A (es)
AR (1) AR090315A1 (es)
AU (1) AU2013203512B2 (es)
CA (1) CA2871159A1 (es)
IN (1) IN2014DN08385A (es)
MX (1) MX2014010940A (es)
TW (1) TW201400499A (es)
WO (1) WO2013138271A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112076330B (zh) 2010-12-30 2023-06-02 法国化学与生物科技实验室 作为病原体灭活剂的二元醇
AU2013296240B2 (en) 2012-08-03 2018-05-17 Lfb Usa, Inc. The use of antithrombin in extracorporeal membrane oxygenation
CN105263319A (zh) 2013-02-13 2016-01-20 法国化学与生物科技实验室 具有经修饰的糖基化的蛋白及其生产方法
BR112015019341A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal
CA2916566A1 (fr) 2013-07-05 2015-01-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Matrice de chromatographie d'affinite
WO2021073518A1 (zh) * 2019-10-17 2021-04-22 中国科学院动物研究所 纤溶酶抑制因子的抑制剂用于预防或治疗子痫前期或子痫的用途
CN113406326B (zh) * 2021-06-01 2022-08-26 大连医科大学 一种用于预测子痫前期的生物学标志物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US20050271660A1 (en) * 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
WO2006007213A1 (en) * 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
US20100062973A1 (en) * 2005-03-11 2010-03-11 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material
WO2007014244A2 (en) * 2005-07-25 2007-02-01 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
US7521632B2 (en) 2006-08-31 2009-04-21 Gaton Corporation Door hinge assembly and enclosure employing the same

Also Published As

Publication number Publication date
CN104321076A (zh) 2015-01-28
KR20140135219A (ko) 2014-11-25
AU2013203512A1 (en) 2013-09-26
MX2014010940A (es) 2015-04-13
WO2013138271A1 (en) 2013-09-19
IN2014DN08385A (es) 2015-05-08
US20140206617A1 (en) 2014-07-24
EP2825194A4 (en) 2015-10-21
TW201400499A (zh) 2014-01-01
EP2825194A1 (en) 2015-01-21
AU2013203512B2 (en) 2016-02-25
JP2015509984A (ja) 2015-04-02
CA2871159A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
AR090315A1 (es) Uso de antitrombina en el tratamiento de pre-eclampsia
BR112015025709A2 (pt) monoterapia com gla para uso em tratamento de câncer
DOP2018000026A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
BR112015022950A2 (pt) cancelamento de ruído de padrão fixo abrangente
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
BR112015032833A2 (pt) métodos e aparelhos para criar um efeito visual em um artigo de borracha
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
ECSP11010905A (es) Uso de ditiina-tetracarboximidas para combatir hongos fitopatógenos
CL2012003625A1 (es) Una composicion acuosa que contiene bromhexina, en donde la composicion tiene una cantidad de azucar-alcoholes inferior a 10 g referida a 100 ml de la composicion; y su uso para la terapia secretorica en enfermedades broncopulmonares agudas y cronicas.
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
UY34382A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
UY33616A (es) Compuestos con estructura de imidazotriazinona
BR112015024281A2 (pt) partículas compósitas e processo para fabricação das mesmas
BR112015000582A2 (pt) método, e composição
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
BR112015005653A2 (pt) Método de promover o desenvolvimento de oócitos maduros e de aumentar a polimerização de actina em tecido ovariano, e uso de um agente que perturba a sinalização na trajetória hippo, ou um agente que age a jusante da sinalização hippo perturbada
BR112018070188A2 (pt) uso de caulim como opacificante
PE20151435A1 (es) Laquinimod para reducir el dano talamico en la esclerosis multiple
BR112015026388A2 (pt) métodos e composições para cicatrização de feridas
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida
BR112014007150A2 (pt) artigos abrasivos de redução de ruído
UY34012A (es) Polisacáridos que comprenden dos sitios de unión a la antitrombina iii, su preparación y su uso como medicamentos antitrombóticos
AR095738A1 (es) Tratamiento para disfunción cognitiva

Legal Events

Date Code Title Description
FB Suspension of granting procedure